DB:0PP

Stock Analysis Report

Executive Summary

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States.

Snowflake

Fundamentals

High growth potential with mediocre balance sheet.

Share Price & News

How has Portola Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 0PP has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-4.5%

0PP

-2.3%

DE Biotechs

0.03%

DE Market


1 Year Return

34.3%

0PP

-6.9%

DE Biotechs

9.9%

DE Market

Return vs Industry: 0PP exceeded the German Biotechs industry which returned -6.9% over the past year.

Return vs Market: 0PP exceeded the German Market which returned 9.9% over the past year.


Shareholder returns

0PPIndustryMarket
7 Day-4.5%-2.3%0.03%
30 Day-1.0%-3.1%4.4%
90 Day-11.7%-9.6%13.6%
1 Year34.3%34.3%-6.7%-6.9%13.4%9.9%
3 Year37.1%37.1%52.7%50.8%25.6%14.6%
5 Year11.9%11.9%5.0%2.7%36.9%18.2%

Price Volatility Vs. Market

How volatile is Portola Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Portola Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 0PP (€24.2) is trading below our estimate of fair value (€84.23)

Significantly Below Fair Value: 0PP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 0PP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 0PP is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 0PP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 0PP is overvalued based on its PB Ratio (9.9x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Portola Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

58.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0PP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: 0PP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 0PP's is expected to become profitable in the next 3 years.

Revenue vs Market: 0PP's revenue (43.2% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: 0PP's revenue (43.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 0PP is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Portola Pharmaceuticals performed over the past 5 years?

-15.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 0PP has a high level of non-cash earnings.

Growing Profit Margin: 0PP's current net profit margins (-275.1%) are higher than last year (-1020.5%).


Past Earnings Growth Analysis

Earnings Trend: 0PP is unprofitable, and losses have increased over the past 5 years at a rate of -15.7% per year.

Accelerating Growth: Unable to compare 0PP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0PP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: 0PP has a negative Return on Equity (-133.91%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Portola Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 0PP's short term assets ($514.5M) exceeds its short term liabilities ($87.5M)

Long Term Liabilities: 0PP's short term assets (514.5M) exceeds its long term liabilities (276.8M)


Debt to Equity History and Analysis

Debt Level: 0PP's debt to equity ratio (131.8%) is considered high

Reducing Debt: Insufficient data to determine if 0PP's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 0PP has a low level of unsold assets or inventory.

Debt Coverage by Assets: 0PP's debt is covered by short term assets (assets are 1.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 0PP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 0PP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Portola Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 0PP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 0PP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 0PP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 0PP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 0PP's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Portola Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average management tenure


CEO

J. Garland (50yo)

1.1yrs

Tenure

US$5,769,031

Compensation

Mr. J. Scott Garland, MBA has been President, Chief Executive Officer and Director at Portola Pharmaceuticals Inc. since October 08, 2018. He was President of Relypsa, Inc., from March 31, 2017 to October  ...


CEO Compensation Analysis

Compensation vs Market: J.'s total compensation ($USD5.77M) is above average for companies of similar size in the German market ($USD1.60M).

Compensation vs Earnings: Insufficient data to compare J.'s compensation with company performance.


Management Age and Tenure

1.5yrs

Average Tenure

55yo

Average Age

Experienced Management: 0PP's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Age and Tenure

7.7yrs

Average Tenure

63.5yo

Average Age

Experienced Board: 0PP's board of directors are considered experienced (7.7 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.


Management Team

  • Mark Gossett

    Senior Vice President of Global Marketing

    • Tenure: 0yrs
  • Mardi Dier (55yo)

    Executive VP

    • Tenure: 13.3yrs
    • Compensation: US$2.52m
  • Bill Lis (55yo)

    Consultant

    • Tenure: 1.3yrs
    • Compensation: US$5.27m
  • Glenn Brame (62yo)

    Executive VP & Chief Technical Operations Officer

    • Tenure: 1.4yrs
    • Compensation: US$3.23m
  • John Moriarty (51yo)

    Executive VP

    • Tenure: 1.7yrs
    • Compensation: US$4.32m
  • J. Garland (50yo)

    President

    • Tenure: 1.1yrs
    • Compensation: US$5.77m
  • Jeet Mahal

    Vice President of Business Development

    • Tenure: 6.8yrs
  • Randy St. Laurent

    Vice President of Sales

    • Tenure: 4.8yrs
  • Ernie Meyer (55yo)

    Executive VP & Chief Human Resources Officer

    • Tenure: 1.3yrs
    • Compensation: US$2.84m
  • Cara Miller

    Vice President of Investor Relations and Corporate Communications

    • Tenure: 0yrs

Board Members

  • Laura Brege (61yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$334.43k
  • Hollings Renton (72yo)

    Independent Chairman

    • Tenure: 9.7yrs
    • Compensation: US$372.43k
  • Jeff Bird (58yo)

    Independent Director

    • Tenure: 16yrs
    • Compensation: US$334.43k
  • Henry Wolff (70yo)

    Independent Director

    • Tenure: 12yrs
    • Compensation: US$338.93k
  • Frank McCormick (69yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Art Weiss

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • David Ginsburg (66yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • John Johnson (61yo)

    Independent Director

    • Tenure: 5.7yrs
    • Compensation: US$576.91k
  • Charles Esmon

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • J. Garland (50yo)

    President

    • Tenure: 1.1yrs
    • Compensation: US$5.77m

Company Information

Portola Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Portola Pharmaceuticals, Inc.
  • Ticker: 0PP
  • Exchange: DB
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.117b
  • Listing Market Cap: US$1.917b
  • Shares outstanding: 77.82m
  • Website: https://www.portola.com

Number of Employees


Location

  • Portola Pharmaceuticals, Inc.
  • 270 East Grand Avenue
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PTLANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2013
0PPDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2013

Biography

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States.  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/16 21:41
End of Day Share Price2019/11/15 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.